7:30 AM ET
8-K
Loan & Debt
Atea Pharmaceuticals $200M Debt Financing with Hercules Capital, Inc.
Atea Pharmaceuticals entered into a $200 million senior secured term loan facility with Hercules Capital, with an initial $65 million drawn at closing. Additional tranches are available upon achieving clinical and commercial milestones related to the bemnifosbuvir and ruzasvir (BEM/RZR) program. The facility matures in November 2031 and carries a floating interest rate starting at a minimum of 9.35%.
- Value
- $200M
- Counterparty
- Hercules Capital, Inc.
- Term
- through Nov 2031